AIM Immunotech Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by AIM Immunotech Inc. on September 11, 2024. The company is incorporated in Delaware and its common stock trades on the NYSE American under the symbol "AIM". The filing primarily addresses executive compensation adjustments and corrections to prior employment agreements.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity metrics. This report focuses exclusively on corporate governance and executive compensation matters rather than financial performance results.
Material Changes
- CEO Compensation Reduction: The cash portion of CEO Thomas K. Equels' short-term compensation was reduced from $750,000 to $650,000.
- Equity Compensation: The $100,000 reduction in cash compensation is being paid in restricted shares of common stock, valued at 100% of the closing price on September 10, 2024.
- Agreement Correction: A clerical error regarding the effective period for compensation changes for Mr. Equels and Mr. Rodino (originally announced August 12, 2024) was corrected. The period for these changes is now confirmed to be the year ending August 12, 2025.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, market outlook, or discussion of general business risks. The primary contingency noted is the formalization of the compensation changes through new amendments to the employment agreements of Thomas K. Equels and Peter W. Rodino, III, which are attached as Exhibits 10.1 and 10.2.
Investor Verification Checklist
- Verify the exact number of restricted shares issued to the CEO by dividing $100,000 by the closing stock price on September 10, 2024.
- Review the attached Exhibits 10.1 and 10.2 to confirm the specific terms of the amended employment agreements.
- Confirm the corrected effective dates for the compensation changes for both the CEO and Mr. Rodino.